Trial record 1 of 1 for:
MTA37
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00422292 |
|
Recruitment Status :
Completed
First Posted : January 15, 2007
Results First Posted : June 2, 2011
Last Update Posted : April 14, 2016
|
Sponsor:
Sanofi Pasteur, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.
Primary Objectives:
- To evaluate the antibody responses induced by Measles, Mumps, Rubella, and Varicella (MMRV) vaccine when administered alone or concomitantly with Menactra vaccine.
- To evaluate the antibody responses induced by Pneumococcal Conjugated Vaccine (PCV) when administered alone or concomitantly with Menactra vaccine.
Observational Objectives:
Safety - To describe the safety profile throughout the course of the study from Day 0 up to 6 months after the last study vaccination[s]) in subjects in the study groups.
Immunogenicity:
- To describe the antibody responses to meningococcal serogroups A, C, Y, and W-135, 30 days after the first and second Menactra vaccine administration in a subset of subjects in the first study group.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Meningococcal Meningitis Measles Mumps Rubella Varicella | Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine Biological: Measles, Mumps, Rubella and Varicella | Phase 3 |
No meningococcal vaccine is presently licensed for the population aged < 2 years in the US, establishing the effectiveness of a quadrivalent polysaccharide conjugate vaccine against invasive meningococcal disease in children aged < 2 years would address this important, currently unmet public health need.
At enrollment, each 9-month old subject will be randomly assigned to a study group and vaccinated. A second vaccination will be administered at 12 months of age. Subjects will provide one blood sample during the trial.
Twelve-month old subjects will also be vaccinated with routine pediatric vaccines and provide one blood sample 30 days after vaccinations in the control group
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1664 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers |
| Study Start Date : | December 2006 |
| Actual Primary Completion Date : | January 2009 |
| Actual Study Completion Date : | April 2009 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Shingles
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Menactra® at 9 and 12 Months
Participants will received Menactra® vaccination at 9 and 12 months of age.
|
Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
0.5 mL dose, intramuscular (IM)
Other Name: Menactra® |
|
Experimental: Menactra® at 9 Months and Menactra® + MMRV at 12 Months
Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
|
Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
0.5 mL dose, IM
Other Name: Menactra® |
|
Experimental: Menactra® at 9 Months and Menactra® + PCV at 12 Months
Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
|
Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
0.5 Ml dose, IM
Other Name: Menactra® |
|
Active Comparator: MMRV + PCV at 12 Months
Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
|
Biological: Measles, Mumps, Rubella and Varicella
0.5 mL dose, SC
Other Names:
|
Primary Outcome Measures :
- Measles, Mumps, Rubella, and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only) [ Time Frame: Day 30 after the 12-month vaccination ]Percentage of participants who had a concentration of ≥ 300 mIU/mL in the enzyme-linked immunosorbent assay (ELISA) or ≥ 120 mIU/mL in the neutralization when the ELISA concentration was less than 300 mIU/mL - for measles; ≥ 500 U/mL (ELISA) or ≥ 60 (1/dil) in the neutralization assay when the ELISA concentration was less than 500 mIU/mL - for mumps; ≥ 10 IU/mL (ELISA) - for Rubella; and ≥ 300 mIU/mL (ELISA) or ≥ 4 (1/dil) Fluorescent antibody to membrane antigen (FAMA) when the ELISA concentration was less than 300 mIU/mL - for varicella.
- Geometric Mean Concentrations (GMCs) of Anti-Pneumococcal Antibodies After Pneumococcal Conjugated Vaccine (PCV) in Groups 3 and 4 [ Time Frame: Day 30 after the 12-month vaccination ]
Other Outcome Measures:
- Percentage of Participants With Anti-Pneumococcal Concentrations ≥ 0.35 μg/mL After Pneumococcal Conjugate Vaccine (PCV) in Group 3 and Group 4 [ Time Frame: Day 30 after 12-month vaccination ]
- Percentage of Participants Reporting a Solicited Injection Site and Systemic Reactions After Menactra® Vaccination at 9 Months of Age [ Time Frame: Days 0 to 7 after vaccination ]
Solicited injection site reactions: Injection site tenderness, injection site erythema, and injection site swelling.
Solicited systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability.
- Percentage of Participants With Solicited Injection Site and Systemic Reactions After Vaccination at 12 Months of Age [ Time Frame: Days 0 to 7 after vaccination ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 9 Months to 12 Months (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria :
- Healthy, as determined by medical history and physical examination
- Aged 9 months (249 to 291 days) for Groups 1, 2, and 3 or aged 12 months (365 to 386 days) for Group 4 at the time of enrollment
- The parent or legal guardian has signed and dated the Institutional Review Board (IRB)-approved informed consent form.
Exclusion Criteria :
- Serious acute or chronic disease (e.g., cardiac, renal, metabolic, rheumatologic, psychiatric, hematologic, autoimmune disorders, diabetes, atopic conditions, congenital defects, convulsions, encephalopathy, blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic system, acute untreated tuberculosis) that could interfere with trial conduct or completion
- Known or suspected impairment of immunologic function
- Acute medical illness within the last 72 hours or a temperature ≥ 100.4ºF (≥38.0ºC) at the time of enrollment.
- History of documented invasive meningococcal disease or previous meningococcal vaccination.
- Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C seropositivity as reported by the parent or legal guardian
- Received either immune globulin or other blood products within the last 3 months, or received injected or oral corticosteroids, or other immunomodulator therapy within 6 weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting < 7 days and individuals (e.g., asthmatics) on a short schedule of oral steroids lasting 3 to 4 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment. Topical steroids are not included in this exclusion criterion.
- Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior to any blood draw. Topical antibiotics and antibiotic drops are not included in this exclusion criterion.
- Suspected or known hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccines or a vaccine containing the same substances. For ProQuad vaccine recipients, this includes a hypersensitivity to gelatin or a history of anaphylactic reactions to neomycin.
- Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM) vaccination.
- Parent or legal guardian unable or unwilling to comply with the study procedures
- Participation in another interventional clinical trial in the 30 days preceding enrollment or planned participation in another clinical trial involving the investigation of a drug, vaccine, medical procedure, or medical device during the subject's trial period.
- Diagnosed with any condition, which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine
- Received any vaccine in the 30-day period prior to receipt of the study vaccines, or scheduled to receive any vaccination other than influenza vaccination and hyposensitization therapy in the 30-day period after receipt of the study vaccines. Hyposensitization therapy and influenza vaccination may be received up to two weeks before or two weeks after receiving the study vaccines. Subjects should not have received their fourth dose of Pneumococcal conjugate vaccine (PCV) or Haemophilus influenzae type b (Hib) vaccine or their first dose of Measles, mumps, rubella, varicella (MMRV) vaccine before enrollment or been scheduled to receive these vaccines outside of the study-specified visits.
- Personal or family history of Guillain-Barré Syndrome (GBS)
- History of seizures, including febrile seizures, or any other neurologic disorder
- Known hypersensitivity to dry natural rubber latex.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00422292
Locations
Show 88 study locations
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
| Study Director: | Medical Director | Sanofi Pasteur Inc. |
Additional Information:
| Responsible Party: | Sanofi Pasteur, a Sanofi Company |
| ClinicalTrials.gov Identifier: | NCT00422292 |
| Other Study ID Numbers: |
MTA37 |
| First Posted: | January 15, 2007 Key Record Dates |
| Results First Posted: | June 2, 2011 |
| Last Update Posted: | April 14, 2016 |
| Last Verified: | April 2016 |
Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):
|
Menactra vaccine Meningococcal meningitis Measles Mumps |
Rubella Varicella vaccines Haemophilus influenzae type b Pneumococcal conjugate vaccine |
Additional relevant MeSH terms:
|
Measles Chickenpox Herpes Zoster Rubella Meningitis, Meningococcal Meningitis Neuroinflammatory Diseases Nervous System Diseases Morbillivirus Infections Paramyxoviridae Infections Mononegavirales Infections RNA Virus Infections Virus Diseases Infections Varicella Zoster Virus Infection |
Herpesviridae Infections DNA Virus Infections Rubivirus Infections Togaviridae Infections Meningitis, Bacterial Central Nervous System Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Meningococcal Infections Neisseriaceae Infections Gram-Negative Bacterial Infections Central Nervous System Infections Central Nervous System Diseases Vaccines Immunologic Factors |